Johnson & Johnson beats Q2 estimates, lifts full-year guidance
Johnson & Johnson (JNJ) reported second-quarter 2025 results that beat analyst expectations and raised its full-year guidance. However, shares slipped about 1% in premarket trading.
Key Numbers
Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although shares slipped about 1% in premarket trading on Wednesday.
Key Financial Results
| Metric | Q2 2025 | Consensus |
|---|---|---|
| Revenue | $12.5B | N/A |
| Adjusted EPS | $2.45 | N/A |
Note: Year-over-year comparisons were not provided in the original source.
Highlights
The company posted adjusted earnings per share of $2.45, beating estimates. Revenue came in at $12.5 billion. No further segment details were disclosed.
Guidance
Johnson & Johnson raised its full-year 2025 guidance, though specific figures were not immediately available.
Stock Reaction
Despite the positive results, JNJ shares fell about 1% in premarket trading, possibly reflecting higher market expectations or broader concerns.
What This Means for Investors
The earnings beat and guidance raise indicate strong operational performance, but the stock dip warrants monitoring for underlying causes such as valuation or market sentiment. Investors should look for further details in upcoming reports.
Frequently Asked Questions
Found this useful? Share it